Incyte Corporation

This study tests whether adding the experimental drug INCB161734 to standard chemotherapy helps people with a certain genetic type of advanced pancreatic cancer (KRAS G12D mutation) live longer or slow their cancer. About 588 adults who have not had prior treatment for their meta…

This early-phase study tests a new drug called INCA036873 in 280 adults with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The main goal is to check the drug's safety and find the right dose. Participants will be closely monitored for…

This study tests whether adding axatilimab to the standard drug ruxolitinib works better for people newly diagnosed with moderate to severe chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. About 120 participants aged 12 and older will receiv…

This study tests an experimental drug called INCB000928 in people with fibrodysplasia ossificans progressiva (FOP), a rare condition where soft tissues turn into bone. The goal is to see if the drug can prevent or reduce new abnormal bone growth. About 98 participants aged 2 and …

This study tests a cream called ruxolitinib in 250 children aged 6 to 12 with nonsegmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the cream can safely bring back color, especially on the face. Participants will use the cream daily for m…

This study tests a new medicine called axatilimab against the best current treatments for children aged 2 to 17 with chronic graft-versus-host disease (cGVHD), a serious complication after a stem cell transplant. Participants must have already tried at least two prior treatments …

This study offers ongoing treatment with tafasitamab for people with blood cancers who are already benefiting from the drug in an earlier study. It aims to keep providing the medicine while monitoring for side effects. About 25 participants will join this extension study.

This study is for people with hidradenitis suppurativa who have already taken part in and benefited from earlier studies of the drug povorcitinib. It aims to provide continued treatment while monitoring long-term safety and how well the drug controls symptoms like abscesses and i…

This study tests a drug called axatilimab in Chinese patients who have chronic graft-versus-host disease (cGVHD) that did not get better with other treatments. cGVHD is a complication after a stem cell transplant where the donor cells attack the patient's body. The goal is to see…

This early-stage study tests a new drug, INCA035784, for safety in 120 adults with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Participants must have a specific gene mutation (CALR) and have tried other treatments. The main goal is to check for side effect…

This early-stage study tests a new drug, INCB161734, in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goal is to check the drug's safety and find the right dose, either alone or with other cancer treatments. About 710 adults whos…

This study tests a new oral drug, INCB123667, against standard chemotherapy for people with a specific type of ovarian cancer that has stopped responding to platinum-based treatments. The trial includes about 466 adults whose tumors have high levels of a protein called cyclin E1.…

This study tests an experimental drug called povorcitinib in 330 adults with prurigo nodularis, a condition causing intense itching and hard skin bumps. The goal is to see if the drug can significantly reduce itch and clear the lesions compared to a placebo over 24 weeks. Partici…

This study tests a cream called ruxolitinib for people with hidradenitis suppurativa, a condition that causes painful, swollen lumps under the skin. About 550 adults with mild to moderate disease will use the cream or a placebo for several weeks. The goal is to see if the cream r…